🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are escalating globally, with data suggesting in excess of 82 million new cases per year. Particularly high rates are seen in the African continent and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the context of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Health officials are particularly alarmed about the increase in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers hope that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This drug, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This authorization signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Outcomes and Global Access

Based on results detailed in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which combines an injection and a pill. The study included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the ability to make available and distribute the drug in many regions with limited resources.

Clinicians treating patients have voiced optimism. The availability of a one-pill regimen of this kind is hailed as a "game-changer" for managing the epidemic. This is considered vital to alleviate the strain of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.